Orchid Orthopedic Solutions has signed an agreement to acquire the Cam Bioceramics coating facility and operations in Suzhou (Cam China), a company that provides hydroxylapatite (HA) plasma coatings in China. Cam Bioceramics, based in Leiden, the Netherlands, specializes in calcium phosphates; the company is Dutch-owned.
Orchid Acquires Cam Bioceramics in China

According to the November 19, 2015 news release: “The acquisition of Cam China strongly commits Orchid to the market in Asia. We will continue to expand our manufacturing platform and coating capabilities in China to support the growing demand from our global and local customers, ” said Christopher Norbye, Orchid’s China-based international executive vice president.
“We are convinced that Orchid is the perfect company to continue the development of the operations and relationships we have built over the last four years in China and I am confident the team in China will have great opportunities to grow the business together with Orchid going forward, ” added Gerard Kok, the founder and owner of Cam Bioceramics.
Norbye told OTW, “Adding the Cam China coating facility supports our long-term strategy to have full value stream services on three continents: North America, Europe and Asia. We are continuing to look at businesses that will support this strategy and be a good fit to our Orchid culture. The timing is something that cannot always be controlled, but when the right opportunity comes, it makes sense to execute.”
Asked about their plans in China over the next one to two years, he noted, “We will ensure success by supporting this facility with the Orchid global coating expertise and offer our customers world class service and quality from China. We will also continue to invest in people, equipment and processes to further grow our capabilities in China.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.